A phase IIa trial studied the effect of the HER2‐targeted antibody pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2‐positive, advanced gastric cancer or cancer of the gastroesophageal junction. Here, ERBB2 is linked to cancer.